Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Cole

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Journal of Experimental Medicine|May 23, 1998
CD3 ligation on immature thymocytes generates antagonist-like signals appropriate for CD8 lineage commitment, independently of T cell receptor specificityM A Basson, U Bommhardt, M S Cole, et al.
The Journal of Experimental Medicine|April 21, 1997
Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergyJ A Smith, J Y Tso, M R Clark, et al.
International Journal of Cancer|July 3, 1998
Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanismsB K Link, S A Kostelny, M S Cole, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1994
The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapyG J Weiner, S A Kostelny, J R Hillstrom, et al.
Transplantation|September 10, 1999
HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitroM S Cole, K E Stellrecht, J D Shi, et al.
International Immunology|June 1, 1995
A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinomaT Bakács, J Lee, M B Moreno, et al.
Cancer Immunology, Immunotherapy : CII|March 1, 1995
Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivoM B Moreno, J A Titus, M S Cole, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Journal of Experimental Medicine|May 23, 1998
CD3 ligation on immature thymocytes generates antagonist-like signals appropriate for CD8 lineage commitment, independently of T cell receptor specificityM A Basson, U Bommhardt, M S Cole, et al.
The Journal of Experimental Medicine|April 21, 1997
Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergyJ A Smith, J Y Tso, M R Clark, et al.
International Journal of Cancer|July 3, 1998
Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanismsB K Link, S A Kostelny, M S Cole, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1994
The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapyG J Weiner, S A Kostelny, J R Hillstrom, et al.
Transplantation|September 10, 1999
HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitroM S Cole, K E Stellrecht, J D Shi, et al.
International Immunology|June 1, 1995
A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinomaT Bakács, J Lee, M B Moreno, et al.
Cancer Immunology, Immunotherapy : CII|March 1, 1995
Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivoM B Moreno, J A Titus, M S Cole, et al.
Pageof 2